Massachusetts biotech incentives eclipsed by competitive states

Massachusetts has made its way over the past half-dozen years to being an undisputed leader in biotechnology and life sciences research. Now it faces an entirely different challenge: staying there.

Cities and states across the country and around the world have escalated their long-simmering efforts to poach from this regionโ€™s concentration of biotech startups and pharmaceutical mega-companies.

California has a new tax break. Texas is spending hundreds of millions of dollars to position itself as โ€œthe third coastโ€ of biomedical research. South Korea is building laboratories and looking for scientists to fill them.

โ€œIโ€™m sweating,โ€ said Robert Coughlin, chief executive of the Massachusetts Biotechnology Council, after spending hours promoting Massachusetts at the BIO International Convention in San Diego last week. โ€œItโ€™s hard to stay on top. Either you continue to improve or you go backwards.โ€

Massachusetts has long been a research hub for the life sciences, boasting world-class universities, teaching hospitals, and other institutions, but in recent years it has achieved new heights.

The state is six years into the Life Sciences Initiative, a $1 billion, decadelong public spending program that offers grants, loans, and other funding for the industry.

Read the full, original story: Rivals to biotech sector sprout all over

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosateโ€”the world's most heavily-used herbicideโ€”pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-05-01-at-1.29.41-PM
Viewpoint: What happens when whole grains meet modern food manufacturing? Labels donโ€™t tell the whole story.
S
As vaccine rejectionism spreads, measles may be taking a more dangerous turn
ChatGPT-Image-Apr-13-2026-02_20_22-PM
Viewpoint: Misinformation infodemic? Why assessing evidence is so challengingย 
Screenshot-2026-04-20-at-2.26.27-PM
Viewpoint โ€” Food-fear world: The latest activist scientists campaign: Cancer-causing additives
ChatGPT-Image-Mar-27-2026-11_47_30-AM-2
FDAโ€™s expedited drug reviews are hailed in some quarters but other approval practices are problematic
Screenshot-2026-03-13-at-12.14.04-PM
The FDA wants to make many popular prescription drugs OTCโ€”a great idea. Hereโ€™s why itโ€™s unlikely to happen
bigstock opioids on chalkboard with rol
GLP podcast: 'Safe injection sites': enabling drug addiction or saving lives?
circular-bioeconomy-should-focus-on-sustainable-wellbeing
GLP podcast: What's wrong with 'doomsday' environmentalism? It's false.
ChatGPT Image May 10, 2026, 08_16_59 PM 2
Overmedicalization? RFK Jr.โ€™s antidepressant crackdown raises conflict questions over his fee stake in Wisner Baum, the tort firm built on suing drug makers
Screenshot-2026-04-12-135256
Bixonimania: The fake disease scam that AI swallowed whole
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.